Basket Updated
0
Items added
Discover the autophagy pathway and its crucial role in cellular homeostasis. Learn more and uncover the mechanisms of cellular self-degradation here.
Expert-reviewed interactive dopamine signaling pathway providing a current overview of Dopamine in Parkinson's Disease. Learn more here.
An antibody shouldn’t be one of the variables in your experiment. Find out why customers rank CST highest for antibody specificity and sensitivity.
Specificity, consistency, and optimized assay conditions are three key elements that help ensure reliable immunofluorescence (IF) staining results each and every time.
Cancer cells adapt mechanisms to evade death by hijacking mechanisms of immune checkpoint control and modulation of the innate immune response via STING.
Highly specific and sensitive rabbit mAbs against B7 family targets, B7-H3 & B7-H4, are proven to outperform existing clones by WB.
Xenophagy provides an important defense against foreign pathogens such as bacteria and viruses by targeting them for degradation through autophagy.
Mitophagy is a well-studied example of selective autophagy. This post explores mitophagy functions and the consequence of excessive or inadequate mitophagy
Autophagy is more than just the bulk degradation of intracellular components. It can also selectively degrade specific organelles, pathogens, and proteins.
Designing or troubleshooting flow cytometry experiments to analyze intracellular signaling? Here’s what you need to know.
Tissue clearing has paved the way for intact brain imaging with molecular phenotyping. The technology is rapidly evolving and shows great potential.
Technical support and customer service from Cell Signaling Technology.
Jan 2008, CST entered into an assay development partnership agreement with TTP LabTech Ltd. (TTPLT.
Dec 2011, CST wins "Best Performing Antibodies" and "Best Breakthrough Products Cancer Research" Categories in Life Science Industry Awards.
CiteAb Names Cell Signaling Technology, "Antibody Company of the Year" and "Researchers’ Choice"
Oct 2007, CST announced the availability of PhosphoScan® profiling technology and PhosphoSite® knowledge base to academic researchers.
Feb 2008, CST announced continued PhosphoScan® proteomics research project with Bristol-Myers Squibb for kinase inhibitor profiling.
Aug 2006, CST announced the publication of discovery research based on its patent-pending PhosphoScan® proteomics technology, which identified a mutant JAK3 tyrosine kinase as a novel driver in acute myeloid leukemia (AML).
Nov 2008, Renewal of a research agreement with Ortho-Biotech Oncology Research & Development, under which CST will employ its patented PhosphoScan® and PTMScan® technologies in research aimed at biomarker discovery and validation for multiple enzyme target classes and lead small-molecule inhibitors.
实验室期望-CST的官方博客，我们将讨论您在工作时的期望，我们将分享提示，技巧和信息，以确保您在工作时的时间达到这些期望。
Expert-reviewed interactive pathway providing a current overview of the molecular and cellular biology of Alzheimer’s Disease.
Expert-reviewed interactive diagrams providing current overviews of neuronal and glial cell markers, as well as links to products from CST.
Cell Signaling Technology (CST) Enters Agreement with Roche for CDx Development
CiteAb Names Cell Signaling Technology "Antibody Company of the Year" and "Antibody Company Succeeding in Cancer Biology"
Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for &quoPTM Antibody Company of the Year" and for a third year in a row with the award for "Researchers’ Choice."
CST is proud to partner with global green chemistry nonprofit Beyond Benign to support the creation of green chemistry teaching resources for STEM education.
